Skip to content

A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients

Carb Control: Low-Carbohydrate Dietary Intervention for Pediatric Patients With Type 2 Diabetes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06902077
Enrollment
40
Registered
2025-03-30
Start date
2025-11-25
Completion date
2027-12-31
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Pediatric type 2 diabetes, Type 2 Diabetes, low carb diet, Low-Carbohydrate Dietary

Brief summary

The purpose of this project is to test the effect of a low carb diet compared to standard carb diet among adolescents with T2D over a 24-week period.

Detailed description

Background Type 2 diabetes (T2D) in teenagers is becoming a growing health concern. In the U.S., the number of children and teens diagnosed with T2D nearly doubled between 2002 and 2018. Experts predict that in the next 40 years, the number of young people with T2D could quadruple. T2D in youth is different from T2D in adults. Teens with T2D have more insulin resistance and their bodies struggle to make enough insulin. Unfortunately, common diabetes medications do not stop the disease from getting worse. Better treatment options for young people with T2D are needed. T2D happens when the body becomes resistant to insulin and the pancreas struggles to keep up. Diet is a key part of managing T2D, but there are no clear guidelines for the best diet for teens with diabetes. In adults, low-carbohydrate diets (LCDs) have been shown to: * Lower blood sugar and improve diabetes control * Improve insulin function and protect the pancreas * Reduce the need for diabetes medications * Help with weight loss, especially in areas of harmful fat like the liver and belly While LCDs have been well-studied in adults, there is very little research on how they affect adolescents with T2D. A few small studies suggest that reducing carbs may help teens with obesity and fatty liver disease, but we need more evidence to know for sure. Study Objective This study will test whether a low-carbohydrate diet (LCD) can help improve blood sugar control and insulin function in adolescents with T2D. The investigators will compare it to the standard diet for diabetes care. How the Study Works The investigators will conduct a randomized controlled trial (RCT), meaning that participants will be randomly placed into one of two groups: * Low-Carb Diet (LCD): 50-80 grams of carbohydrates per day * Standard Diabetes Diet (SCD): A diet based on current guidelines The study will last 24 weeks (6 months). Participants will keep food records and meet with a dietitian to track their progress. What The Study Will Measure The investigators will test whether the low-carb diet helps improve: * Blood sugar control (measured by HbA1c) * Insulin function and resistance (measured by an oral glucose tolerance test) * Weight and fat loss, especially in harmful fat stores * Triglycerides and cholesterol levels * Need for diabetes medications What The Study Expect to Find The investigators believe that teens who follow a low-carb diet will have: * Better blood sugar control * Less insulin resistance * More weight loss, especially from harmful fat * Lower triglycerides and better cholesterol levels * Less need for diabetes medications This study will help us understand whether reducing carbs is a safe and effective way to improve diabetes in teens.

Interventions

BEHAVIORALlow carb diet

diet based on low carb with max 50-80 grams of carbohydrates daily

BEHAVIORALdiabetic diet

Balanced diet based on standard of care recommendations for type 2 diabetes

Sponsors

Children's of Alabama
CollaboratorOTHER
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age 12-18 * Diabetes diagnosis \>3 months to ensure stable baseline glycemic control * HbA1C between 6.5- 8.5% * BMI \>85th percentile * Negative pancreatic autoantibodies * Stable dose of anti-diabetic drugs GLP-1, metformin, SGLT-2 inhibitors, for 3 months

Exclusion criteria

* Current insulin treatment * Renal impairment measured as creatinine \> 1 mg/dL * Hepatic dysfunction measured as AST and ALT \>100 IU/ml

Design outcomes

Primary

MeasureTime frameDescription
Change in HbA1cBase line, 3 months, 6 monthsHbA1c levels will be measured to assess long-term glycemic control. Unit of Measure: Percent (%).
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)Base line, 3 months, 6 monthsHOMA-IR will be calculated using fasting glucose and insulin values collected at baseline. The formula used is: HOMA-IR = (fasting insulin \[μU/mL\] × fasting glucose \[mg/dL\]) / 405. This index reflects hepatic insulin resistance. Units of Measure: Unitless index
Whole Body Insulin Sensitivity Index (WBISI)Base line, 3 months, 6 monthsWBISI will be calculated using values from the 2-hour Oral Glucose Tolerance Test (OGTT). The formula is: WBISI = 10,000 / √(fasting glucose × fasting insulin × mean OGTT glucose × mean OGTT insulin). This index reflects peripheral insulin sensitivity. Units of Measure: Unitless index

Secondary

MeasureTime frameDescription
Change in BMIBase line, 3 months, 6 monthsWeight and height will be combined to report BMI. Weight in kilograms divided by height in meters squared (kg/m²). Height will be measured using a wall-mounted stadiometer. Unit of Measure: kg/m²
Change in body compositionBase line, 3 months, 6 monthsBody composition will be assessed using a validated bioelectrical impedance analysis (BIA) scale, which estimates fat mass, lean mass, and total body water. Measurement Tool: Bioelectrical impedance analysis (BIA) scale Unit of Measure: Percent body fat (%) and lean mass (%)
Change in blood pressureBase line, 3 months, 6 monthsSystolic and diastolic blood pressure will be measured in triplicate using an automated oscillometric blood pressure monitor after the participant has been seated quietly for 5 minutes. Measurement Tool: Automated oscillometric blood pressure monitor Unit of Measure: Millimeters of mercury (mmHg)
Change in lipid profileBase line, 3 months, 6 monthsFasting lipid profile will be assessed via venous blood sample. Parameters will include total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Unit of Measure: Milligrams per deciliter (mg/dL)

Countries

United States

Contacts

Primary ContactOrtal Resnick, MD
oresnick@uabmc.edu205-638-9107

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026